Acteurs : Acteur Elisabeth LUPORSI

Dr Elisabeth LUPORSI
Dr Elisabeth LUPORSICentre Alexis VautrinDépartement d’Oncologie Médicale Centre Régional de Lutte contre le Cancer
54511 Vandoeuvre les Nancy cedex Tel : +33 3 83 59 84 64Fax : +33 3 83 59 83 59

e/m : [email protected]

Equipe de recherche
Equipe L05 – Philippe JONVEAUX • Equipe L40 – Dominique SPAETH •
Aires d’expertise
Clinique:Oncologie Médicale
Axes du CGE
5 : Compréhension et maîtrise des échecs thérapeutiques
Equipe L05

  • Pierre BORDIGONI
  • Philippe JONVEAUX
  • Bruno LEHEUP
  • Philippe MANGIN
  • Christophe PHILIPPE
  • Mylène VALDUGA

Equipe L40

  • Maria RIOS
  • Dominique SPAETH
  • Lionel UWER
  • Béatrice WEBER
Equipe L05

2005 – LYMTK (porteur : Eric DECONINCK)
Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase and a cell surface marker in allogeneic haematopoietic transplantation

Equipe L40


Luporsi E. [Methodological aspects on new protocols in oncology] Bull Cancer. 2008 Oct;95(10):979-83. Review

Namer M, Luporsi E, Gligorov J, Lokiec F, Spielmann M. [The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer] Bull Cancer. 2008 Oct 1;95(9):871-80. Review

Hery M, Bonneterre J, Roche H, Luporsi E, Kerbrat P, Namer M, Fumoleau P, Monnier A, Fargeot P. Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial. Bull Cancer. 2006 Oct 1;93(10):E109-14.

Namer M, Fargeot P, Roche H, Campone M, Kerbrat P, Romestaing P, Monnier A, Luporsi E, Montcuquet P, Bonneterre J. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials. Ann Oncol. 2006 Jan;17(1):65-73.

Fumoleau P, Roche H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ, Luporsi E. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006 Jan;17(1):85-92. Epub 2005 Oct 26.

Mauriac L, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Sigal-Zafrani B, Dilhuydy JM, Acharian V, Balu-Maestro C, Blanc-Vincent MP, Cohen-Solal C, De Lafontan B, Dilhuydy MH, Duquesne B, Gilles R, Lesur A, Shen N, Cany L, Dagousset I, Gaspard MH, Hoarau H, Hubert A, Monira MH, Perrie N, Romieu G. Summary version of the Standards, Options and Recommendations for nonmetastatic breast cancer (updated January 2001). Br J Cancer. 2003 Aug;89 Suppl 1:S17-31.

Dilhuydy JM, Luporsi E, Leichtnam-Dugarin L, Vennin P, Hoarau H. [Radiotherapy of breast cancer] Cancer Radiother. 2003 Jun;7(3):213-21.

Fumoleau P, Kerbrat P, Romestaing P, Fargeot P, Bremond A, Namer M, Schraub S, Goudier MJ, Mihura J, Monnier A, Clavere P, Serin D, Seffert P, Pourny C, Facchini T, Jacquin JP, Sztermer JF, Datchary J, Ramos R, Luporsi E. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol. 2003 Jan 15;21(2):298-305.

Pourel N, Peiffert D, Lartigau E, Desandes E, Luporsi E, Conroy T. Quality of life in long-term survivors of oropharynx carcinoma. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):742-51.

Peiffert D, Giovannini M, Ducreux M, Michel P, Francois E, Lemanski C, Mirabel X, Cvitkovic F, Luporsi E, Conroy T, Gerard JP. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann Oncol. 2001 Mar;12(3):397-404.

Luporsi E, Vanlemmens L, Coudert B. 6 cycles of FEC100 vs 6 cycles of epirubicin-docetaxel as neoadjuvant chemotherapy in operable breast cancer patients : preliminary results of a randomized phase II trial of GIREC S01. Cancer Conference Highlights 2000;4:2-4.
home-9426600pixel-3838769uguest-4657732 poweredby-9827486